Disruption of group IVA cytosolic phospholipase A 2 attenuates myocardial ischemia-reperfusion injury partly through inhibition of TNF-α-mediated pathway

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 10, 2012, Pages

  Saito, Yukio ^a   Watanabe, Kazuhiro ^a   Fujioka, Daisuke ^a   Nakamura, Takamitsu ^a   Obata, Jun Ei ^a   Kawabata, Kenichi ^a   Watanabe, Yosuke ^a   Mishina, Hideto ^a   Tamaru, Shun ^a   Kita, Yoshihiro ^b   Shimizu, Takao ^b   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Arachidonic acid; Etanercept; Gene knockout mouse; Leukotriene; Phospholipase A 2

Indexed keywords

ARACHIDONIC ACID; CYTOSOLIC PHOSPHOLIPASE A2; LEUKOTRIENE B4; PHOSPHOLIPASE A2 GROUP IV; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ANIMALS; CELLS, CULTURED; GROUP IV PHOSPHOLIPASES A2; IMMUNOGLOBULIN G; LEUKOTRIENE B4; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; THROMBOXANE B2; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84861120916     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00955.2011     Document Type: Article

References (40)

1. 2 regulation of arachidonic acid mobilization. FEBS Lett 531: 2-6, 2002.
2. Birnbaum Y, Long B, Qian J, Perez-Polo JR, Ye Y. Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR--independent manner. Basic Res Cardiol 106: 431-446, 2011.
3. Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, Sapirstein A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 390: 622-625, 1997.
4. Bonventre JV, Sapirstein A. Group IV cytosolic phospholipase A2 (PLA2) function: insights from the knockout mouse. Adv Exp Med Biol 507: 25-31, 2002.
5. Caro AA, Cederbaum AI. Role of cytochrome P450 in phospholipase A2-and arachidonic acid-mediated cytotoxicity. Free Radic Biol Med 40: 364-375, 2006.
6. Dawn B, Guo Y, Rezazadeh A, Wang OL, Stein AB, Hunt G, Varma J, Xuan YT, Wu WJ, Tan W, Zhu X, Bolli R. Tumor necrosis factor-α does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol 37: 51-61, 2004.
7. 2-mediated hydrolysis of cardiac phospholipids: the use of molecular and transgenic techniques. Mol Cell Biochem 180: 65-73, 1998.
8. Defer N, Azroyan A, Pecker F, Pavoine C. TNFR1 and TNFR2 signaling interplay in cardiac myocytes. J Biol Chem 282: 35564-35573, 2007.
9. 2. Prostaglandins Leukot Essent Fatty Acids 69: 87-97, 2003.
10. Flaherty MP, Guo Y, Tiwari S, Rezazadeh A, Hunt G, Sanganalmath SK, Tang XL, Bolli R, Dawn B. The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. J Mol Cell Cardiol 45: 735-741, 2008.
11. Fujioka D, Saito Y, Kobayashi T, Yano T, Tezuka H, Ishimoto Y, Suzuki N, Yokota Y, Nakamura T, Obata J, Kanazawa M, Kawabata K, Hanasaki K, Kugiyama K. Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice. Circulation 117: 2977-2985, 2008.
12. Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, Nithipatikom K. Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc Res 68: 18-25, 2005.
13. 2. J Lipid Mediat Cell Signal 12: 131-137, 1995.
14. Gu Q, Yang XP, Bonde P, DiPaula A, Fox-Talbot K, Becker LC. Inhibition of TNF-α reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog. J Cardiovasc Pharmacol 48: 320-328, 2006.
15. Gurevitch J, Frolkis I, Yuhas Y, Lifschitz-Mercer B, Berger E, Paz Y, Matsa M, Karmer A, Mohr R. Anti-tumor necrosis factor-alpha improves myocardial recovery after ischemia and reperfusion. J Am Coll Cardiol 30: 1554-1561, 1997.
16. Haq S, Kilter H, Michael A, Tao J, O'Leary E, Sun XM, Walters B, Bhattacharya K, Chen X, Cui L, Andreucci M, Rosenzweig A, Guerrero JL, Patten R, Liao R, Molkentin J, Picard M, Bonventre JV, Force T. Deletion of cytosolic phospholipase A2 promotes striated muscle growth. Nat Med 9: 944-951, 2003.
17. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61: 448-460, 2004.
18. Hayakawa M, Ishida N, Takeuchi K, Shibamoto S, Hori T, Oku N, Ito F, Tsujimoto M. Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor. J Biol Chem 268: 11290-11295, 1993.
19. Hii CS, Huang ZH, Bilney A, Costabile M, Murray AW, Rathjen DA, Der CJ, Ferrante A. Stimulation of p38 phosphorylation and activity by arachidonic acid in HeLa cells, HL60 promyelocytic leukemic cells, and human neutrophils. Evidence for cell type-specific activation of mitogenactivated protein kinases. J Biol Chem 273: 19277-19282, 1998.
20. Hoeck WG, Ramesha CS, Chang DJ, Fan N, Heller RA. Cytoplasmic phospholipase-A2 activity and gene-expression are stimulated by tumornecrosis-factor: dexamethasone blocks the induced synthesis. Proc Natl Acad Sci USA 90: 4475-4479, 1993.
21. Jupp OJ, Vandenabeele P, MacEwan DJ. Distinct regulation of cytosolic phospholipase A2 phosphorylation, translocation, proteolysis and activation by tumour necrosis factor-receptor subtypes. Biochem J 374: 453-461, 2003.
22. Kita Y, Ohto T, Uozumi N, Shimizu T. Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim Biophys Acta 1761: 1317-1322, 2006.
23. Kleinbongard P, Heusch G, Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 127: 295-314, 2010.
24. Krönke M, Adam-Klages S. Role of caspases in TNF-mediated regulation of cPLA(2). FEBS Lett 531: 18-22, 2002.
25. Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, Opie LH. Pharmacological preconditioning with tumor necrosis factoralpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 112: 3911-3918, 2005.
26. Leslie CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 272: 16709-16712, 1997.
27. Maekawa N, Wada H, Kanda T, Niwa T, Yamada Y, Saito K, Fujiwara H, Sekikawa K, Seishima M. Improved myocardial ischemia/ reperfusion injury in mice lacking tumor necrosis factor-α. J Am Coll Cardiol 39: 1229-1235, 2002.
28. 2. Biol Pharm Bull 27: 1158-1164, 2004.
29. Nakanishi M, Rosenberg DW. Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta 1761: 1335-1343, 2006.
30. Poeckel D, Funk CD. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res 86: 243-253, 2010.
31. 2 and C in myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol 260: H877-H883, 1991.
32. Sen A, Buja LM, Willerson JT, Chien KR. Membrane phospholipid metabolism during myocardial ischaemia: past, present and future. Basic Res Cardiol 82, Suppl 1: 121-125, 1987.
33. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 49: 123-125, 2009.
34. Sugano M, Hata T, Tsuchida K, Suematsu N, Oyama J, Satoh S, Makino N. Local delivery of soluble TNF-alpha receptor 1 gene reduces infarct size following ischemia/reperfusion injury in rats. Mol Cell Biochem 266: 127-132, 2004.
35. Tabuchi S, Uozumi N, Ishii S, Shimizu Y, Watanabe T, Shimizu T. Mice deficient in cytosolic phospholipase A2 are less susceptible to cerebral ischemia/reperfusion injury. Acta Neurochir Suppl 86: 169-172, 2003.
36. Taketo MM, Sonoshita M. Phospolipase A2 and apoptosis. Biochim Biophys Acta 1585: 72-76, 2002.
37. Toufektsian MC, Robbez-Masson V, Sanou D, Jouan MG, Ormezzano O, de Leiris J, Boucher F. A single intravenous sTNFR-Fc administration at the time of reperfusion limits infarct size-implications in reperfusion strategies in man. Cardiovasc Drugs Ther 22: 437-442, 2008.
38. 2. Cloning, tissue distribution, and functional expression of two novel mouse group II enzymes. J Biol Chem 274: 31195-31202, 1999.
39. Yano T, Fujioka D, Saito Y, Kobayashi T, Nakamura T, Obata JE, Kawabata K, Watanabe K, Watanabe Y, Mishina H, Tamaru S, Kugiyama K. Group V secretory phospholipase A2 plays a pathogenic role in myocardial ischaemia-reperfusion injury. Cardiovasc Res 90: 335-343, 2011.
40. 2 activities for the treatment of inflammatory conditions. Biochim Biophys Acta 1761: 1373-1382, 2006.